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ABSTRACT  
 
Purpose. The effects of pioglitazone on sildenafil 
responsiveness in men with erectile dysfunction 
(ED) and a history of poor response to sildenafil 
were assessed. Methods. In a double-blinded study, 
38  men aged 47 ± 1.5 years with moderate-to-
severe ED and poor response to sildenafil were 
randomly assigned to take a premedication of 
pioglitazone 30 mg (n=19) or placebo (n=19) once 
daily for 9 weeks along with on-demand use of 
sildenafil during the last month of pioglitazone- 
treatment. Erectile function (EF) scores, assessed by 
EF domain of International Index of Erectile 
Function (IIEF), along with responses to Global 
Assessment Questions (GAQs) were major outcome 
measures. Serum levels of total testosterone (T), 
dehydroepiandrosterone sulfate (DHEAS), glucose, 
lipid profile and liver function test were minor 
outcome measures. Results. Pioglitazone 
significantly improved major outcome measures 
compared with placebo. The decrease from baseline 
of total cholesterol level was more in pioglitazone- 
than in placebo-treated groups. In 84% (32 out of 
38) of the sildenafil poor-responders, at least one of 
the associated risk factors of ED was found. There 
was undiagnosed hypercholesterolemia in 34% of 
the subjects. Serum levels of T, DHEAS, glucose 
and other parameters remained unchanged in both 
groups. The intervention was well tolerated. 
Conclusions. Pioglitazone increased sildenafil 
response to improve ED of men with prior sildenafil 
failure and seems to be safe based on the present 
preliminary study. This improvement is likely 
regardless of fasting glucose and sex hormones 
levels.  
 
 
 
 
INTRODUCTION 
 
Erectile dysfunction (ED) is a prevalent and chronic 
disorder in men over 40 years old (1, 2) and its 
incidence has increased  because of  limited 
physical activity and high calorie intake associated  
with modern lifestyle (3). Common in risk factors, 
ED is often observed in patients with cardiovascular 
co-morbidities and precedes coronary artery disease 
(4, 5). 
 In penile erection, nitric oxide (NO)-activated 
soluble guanylyl cyclase synthesizes cyclic 
guanosine monophosphate (cGMP) which results in 
relaxation of arterial and trabecular smooth 
muscles. Sildenafil augments these smooth muscle 
relaxations by inhibition of phosphodiesterase-5 
(PDE-5), the enzyme that breakdowns cGMP.  
 Even  though  sildenafil  has  been   extensively 
prescribed as the first line drug in treatment of ED 
for years, there are reports of sildenafil 
discontinuation mainly due to the lack of 
effectiveness in more than 70% of men who stop 
sildenafil usage (6). Even after optimized  
instruction for sildenafil usage (7) or switching to 
more potent drugs of  PDE-5 inhibitors family, with 
either on-demand or daily usage, the success rate of 
intercourse attempts could not reach more than 50% 
(8, 9).  Apart from oral treatments for ED, 
alternative choices such as intracavernousal 
injectable  drugs,   penile   protheses    and   vacuum 
devices     have     disadvantages     including    cost, 
invasiveness and rather artificial sexual 
relationship. 
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Conclusively, for a considerable percentage of men 
with ED who are seeking new treatment modalities, 
planning new therapeutic measures is necessary. 
 Because of ambiguities and controversies on 
common findings in sildenafil non-responders, there 
is no definite clinical  criteria to predict sildenafil 
failure (10, 11), although men with diabetic and 
neurogenic ED have a higher dissatisfaction rate 
(6). Ineffectiveness of sildenafil in ED has been 
shown by a few studies from genetical, 
physiological, histopathological and hemodynamic 
aspects. It is suggested that endothelial nitric oxide 
synthase (NOS 3) and angiotensin converting 
enzyme (ACE) genotypes influence the erectile 
response to sildenafil (12). Severe vascular lesions 
and atrophy of smooth muscle cells (SMCs) were  
observed in sildenafil nonresponders (10). It has 
been showed  that response to sildenafil could not 
be predicted by  endothelial and  autonomic 
systemic function tests, but in diabetic men it 
appears to be related to the initial degree of ED 
(13). Doppler ultrasonography studies of penile 
vessels showed poor rigidity response to 
intracavernous injection of vasodilators, penile 
arterial insufficiency and veno-occlusive 
dysfunction (14, 15). Based on some associated 
findings in this complex and multi-factorial 
disorder, drugs that maintain the structure and 
function of penile vasculature by preventing 
endothelial and SMCs dysfunction and damage, 
may improve response to sildenafil. 
 In optimizing response to sildenafil, the 
candidate drug must have a unique safety profile: 1-
high safety especially in geriatrics as the leading 
age group of ED; 2- few interactions with drugs 
used for co-morbid diseases and with sildenafil 
especially for the risk of acute hemodynamic-
induced events. Preliminary studies have shown 
improved response to sildenafil by quinapril and 
atorvastatin (16, 17). Peroxisome  prolifrator-
activated receptor γ ligands (PPARγ), including  
pioglitazone, demonstrated beneficial effects on ED 
predisposing factors such as endothelial 
dysfunction, oxidative stress, metabolic disorders, 
atherosclerosis and inflammation (18, 19). 
Promisingly, pioglitazone  has already been shown 
to prevent veno-occlusive ED in diabetic rats by a 
mechanism independent of glycaemic control (20). 
Therefore, the present study was conducted to 
examine whether premedication with pioglitazone 
is devoid of any adverse drug events and can 
improve responsiveness to sildenafil in men with 
ED. 
 
METHODS 
 
Subjects 
 
Study population were 38 men (age: 35-70) with 
ED ranging from moderate to severe as defined by 
International Index of Erectile Function (IIEF) 
questionnaire (21, 22). They had to have a stable 
sexual relationship and inadequate response to 
sildenafil citrate. Poor response to sildenafil was 
defined as: having the experience of at least four 
unsuccessful intercourse attempts in nonsuccessive 
occasions after being oriented to use the highest 
tolerable and therapeutic dose (≤100 mg) with 
respect to timing relative to meals, use of 
concomitant medications and adequate sexual 
stimulation. Subjects were excluded from 
participation in respect to any of the followings: 1- 
existing disease: neuropathic (diabetic/nondiabetic), 
endocrinopathic and psychogenic ED, anatomical 
penile abnormality, heart failure (class II - IV), 
serum alanine aminotransferase (ALT) > two fold 
the upper limit of normal values, unstable 
cardiovascular hemodynamic (e.g. coronary 
syndrome, hypotension); 2- medications: substance 
abuse, nitrate and steroid regimens; 3- assessment 
tool (IIEF questionnaire) limitations: low sexual 
desire and EF score <5, sexual dysfunction in 
partner, lack of a stable heterosexual relationship 
(21, 22). The study was conducted in accordance 
and conformation with the Declaration of Helsinki. 
The protocol was reviewed and approved by the 
ethical committee board of Razi Institute for Drug 
Research, Iran University of Medical Sciences. 
 
Study design  
 
This study was designed as a prospective, 
randomized, placebo-controlled, double-blinded 
trial. Subjects enrolled voluntarily following an 
announcement in the Iran University of Medical 
Sciences. The same physician carried out all the 
study interviews and examinations. Signed written 
informed consent was obtained from each subject 
after full oral and written explanation of the 
purpose, nature, duration and risk of all procedures 
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for the patients. All subjects were clinically 
assessed based on a medical/sexual history and 
physical examination including measurements of 
body mass index (BMI) and waist to hip ratio 
(W/H). Following a 4 weeks run-in period for 
sildenafil trial, baseline self-reported questionnaires 
and blood tests were obtained from all patients. 
Eligible patients were assigned to receive either 
pioglitazone 30 mg once daily or matching placebo 
according to a randomization table for nine weeks. 
All patients were requested to have intercourse at 
least once weekly in the last month of pioglitazone 
treatment along with on-demand use of sildenafil. 
The laboratory staffs involved in the intervention 
were not aware of the group assignment. Medical 
visits were scheduled at 4-weeks intervals for 12 
weeks to check possible adverse events, lifestyle 
changes and patients’ compliance. For the second 
time, at the end of intervention period, self-
completed questionnaires and blood tests were 
obtained from the patients. BMI > 28.7 kg/m², 
diabetes, hypercholesterolemia, hypertension and 
smoking were regarded as associated risk factors of 
ED (2-5, 27).  
 
Erectile dysfunction assessment 
 
In this study, a specific version of IIEF 
questionnaire, i.e. erectile function (EF) domain, 
was used as the assessment instrument for 
measurement of erectile function and interventional 
efficacy (21). As the gold standard instrument, the 
IIEF is an extensively used and highly validated 
instrument for the evaluation of sexual function in 
men especially in clinical trials(21-24). EF domain 
is a 6 items version of IIEF questionnaire that 
grades erectile function by responses to six specific 
questions of IIEF questionnaire; Question 1-5 are 
related to EF segment of IIEF and the last question 
concerns erectile confidence, i.e., question 15 IIEF 
(25, 26). The scores of EF domain of IIEF were 
clinically interpreted as: no ED >26, mild ED = 22 
to 25, mild-to-moderate ED=17 to 21, moderate ED 
= 11 to16 and  severe ED <10 (25). 
 Besides the use of EF domain of IIEF for 
definition of functional severity of ED for inclusion 
(IIEF EF domain <17), it is also used for 
measurement of the impact size of pioglitazone on 
sildenafil efficacy in erectile function by comparing 
the secondary IIEF EF domain scores with the 
baseline scores (22). In addition, as qualitative 
measures, two questions of global assessment 
questions(GAQs) was asked from the patients at 
study end  point (22):1- ‘‘Has the treatment you 
have been taking during this study improved your 
erections?” (GAQ Q1) and ‘‘If yes, 2- Has the 
treatment improved your ability to engage in sexual 
activity?”(GAQ Q2).  
 
Laboratory assessment  
 
Laboratory blood tests were done for all subjects at 
the beginning and at the end of study. Serum 
samples were obtained after an overnight fasting 
and immediately processed and kept frozen at -
20°C until the assay was carried out. Serum level of 
glucose, total cholesterol (TC), high density 
lipoprotein cholesterol (HDL), low density 
lipoprotein (LDL), triglycerides (TG), aspartate 
aminotransferase (AST) and alanine 
aminotransferase (ALT) levels. Serum glucose was 
measured by glucose-oxidase method. Serum lipid 
levels, ALT and AST were assayed directly by 
standard enzymatic methods. Total testosterone (T) 
and Dehydroepiandrosterone sulfate (DHEAs) were 
measured with available radioimmunologic kits 
from Biosourse, Belgium (reference limit: 1.34-6.25 
ng/ml) and from Immunotech, France (reference 
limit: 133-441 mcg/dl). Supported by external 
quality control, lab analysis was done in 
Comprehensive Hemophilia Care Center (CHCC) 
of Iran, a member of UK National External Quality 
Assessment Service (UKNEQAS). 
 
Statistical analysis  
 
Erectile function scores was regarded as the major 
outcome measure of present study and values of 
laboratory biomarkers were considered to be the 
minor outcome measures. Continuous variable data 
were analyzed by two-tailed Student’s unpaired t-
test to assess inter-group differences and paired t-
test to assess the longitudinal differences in each 
group. For discrete variables, chi-square test was 
used to assess differences in proportions of 
incidence between the two groups. Correlations 
between changes in variables were assessed with 
Pearson’s correlation coefficient. Data were 
expressed as mean ± SEM. In all tests, p < 0.05 (2-
tailed) was considered to be statistically significant.  
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RESULTS 
 
Of 45 men who were re-challenged for sildenafil, 
40 men (88%) were true poor-/non-responders and 
entered the study. Thirty eight men (95 %) 
completed the study. Two subjects dropped out, one 
in placebo group due to urgent coronary bypass 
surgery and one in drug group for a job offer in 
another city. The prevalence of associated risk 
factors was similar in both groups. 84% of patients 
(32 out of 38) had at least one risk factor and 47% 
of patients (18 out of 38) had two risk factors. 
Regarding a threshold of 195 mg/dl for total 
cholesterol, one third of all participants (13 out of 
38) were unaware of their hypercholestrolemia until 
their first blood test in this study. Baseline 
characteristics and measured data of subjects are 
shown in Table 1 & 2. 
 There were no statistically significant 
differences between the drug and control groups 
with respect to baseline characteristics, EF domain 
scores and laboratory parameters except for TG 
level, which were higher in placebo group (p< 
0.02). The latter was probably influenced by 
undiagnosed familial hypertriglyceridemia (TG = 
599 mg/dl) in one patient. 
 
Erectile function profile 
 
Erectile function score improved in the pioglitazone 
group, but remained stable in the placebo group. 
  
 
 
The mean EF domain of IIEF score was 
significantly increased from 13.32 ± 0.60 to 17.63 ± 
1.05 in pioglitazaone group compared to the 
placebo group in which the EF score changed from 
14.11 ± 0.56 to 14.32 ± 0.73,( p < 0.02), Figure-1. 
Consequently, at the end point of intervention, the 
mean changes of IIEF EF domain score (∆ EF) 
from baseline was significantly higher in the 
pioglitazone  group  compared to the mean  changes 
in placebo group (4.32 ± 0.7 vs. 0.21 ± 0.44, p< 
0.001). 
 In drug group, compared with placebo, the 
mean response to every six questions of EF domain 
improved and this improvement was significant (p 
<0.03) with respect to erection frequency (IIEF 
Q1), erection maintenance frequency (IIEF Q4) and   
erection maintenance ability (IIEF Q5). According 
to clinical classification of IIEF EF domain scores, 
stage of ED in the pioglitazone group raised from 
moderate ED range level to the mild-to-moderate 
range level. At 9 weeks, the proportion of positive 
responses to the GAQs was significantly greater in 
patients receiving pioglitazone (11/19) than in 
patients receiving placebo (2/19) Table- 3. 
 In pioglitazone group, the difference between 
the mean change of EF scores in diabetics and 
nondiabetics (3.16 ±1.27 vs 4.84 ± 0.84, 
respectively) was not significant. Also, in diabetics 
of drug and control groups, the mean changes of EF 
scores (3.16 ± 1.27 vs - 0.25 ± 0.25, respectively) 
were not significantly different. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Baseline characteristics and prevalence of erectile dysfunction risk factors in study subjects. 
 
 Total Placebo Pioglitazone 
n 38 19 19 
Age (yr) 47 ± 1.45 45 ± 1.67 49 ± 2.34 
BMI > 28.7 (Kg/m²)  16 (42%) 8 (42%) 8 (42%) 
Diabetes  10 (26%) 4 (21%) 6 (32%) 
Hypertension  8 (21%) 4 (21%) 4 (21%) 
Hypercholestrolemia  13 (34%) 6 (32%) 7 (37%) 
Smoking  6 (16%) 4 (21%) 2 (11%) 
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Table 2.  Measured variables and IIEF EF domain scores of study subjects at baseline and endpoint. 
 
 Placebo (n=19)  Pioglitazone (n=19)  
 Week 0 Week 9  Week 0 Week 9 p1 
 
p2 
 
BMI, Kg/m2 28.79 ± 1.32 28.70 ± 1.33  28.60 ± 1.22 28.68 ± 1.20 0.916 0.990 
W/H 0.97 ± 0.01 0.971 ± 0.01  0.96 ± 0.01 0.95 ± 0.01 0.403 0.253 
SBP, mmHg 127.37 ± 3.573 126.58 ± 3.86  129.71 ± 3.84 127.94 ± 3.61 0.632 0.692 
DBP, mmHg 81.05 ± 2.28 80 ± 2.16  83.82 ± 2.36 82.35 ± 2.33 0.736 0.805 
FBS, mg/dL 110.90 ± 7.53 104.58 ± 3.98  127.26 ± 13.55 115.32 ± 12.02 0.298 0.402 
∆FBS, mg/dL -6.32 ± 5.905  -11.95 ± 6.90 0.539  
Cholestrol, 
mg/dL 197.34 ± 8.94 200.90 ± 9.52  198 ± 8.38 183.47 ± 7.80 0.957 0.165 
∆Cholestrol, 
mg/dL 3.56 ± 6.35  -14.53 ± 4.03 0.022*  
LDL mg/dL 102.13 ± 5.89 99.70 ± 4.70  106.63 ± 5.31 97.91 ± 5.34 0.574 0.803 
∆LDL, mg/dL -2.43 ± 4.49  -8.721 ± 2.66 0.236  
HDL, mg/dL 34.67 ± 1.99 35.33 ± 1.98  37.98 ± 2.36 38.86 ± 2.27 0.290 0.248 
∆HDL mg/dL 0.65 ± 1.34  0.88 ± 0.98 0.893  
Triglycerides 
mg/dL 215.21 ± 30.19 234.11±38.85  130.368± 14.702 128.789±18.28 0.016* 0.019* 
∆triglycerides 
mg/dL 18.90 ± 22.16  -1.58 ± 10.88 0.412  
AST mg/dL 24.63 ± 2.11 24.12 ± 1.28  21.37 ± 1.56 21.95 ± 1.24 0.221 0.232 
∆AST mg/dL -0.53 ± 1.40  0.58 ± 1.248 0.559  
ALT, mg/dL 33.68 ± 4.24 36.32 ± 3.16  26.37 ± 3.58 28.79 ± 2.31 0.195 0.062 
∆ALT, mg/dL 2.63 ± 2.74  2.42 ± 2.44 0.954  
Testosterone 
ng/mL 3.66 ± 0.33 3.55 ± 0.36  4.38 ± 0.23 4.257 ± 0.25 0.081 0.117 
∆Testosterone, 
ng/ml -0.107 ± 0.203 -0.118 ± 0.226 0.973  
DHEAS,  
mcg/dL 162.71 ± 15.08 156.21±16.44  124.40 ± 13.00 119.12 ± 11.16 0.062 0.070 
∆DHEAS, 
mcg/dL            -6.499 ± 8.363  -5.284 ± 6.895 0.911  
IIEF EF 
Domain 14.11 ± 0.56 14.32 ± 0.73  13.32 ± 0.60 17.63 ± 1.05 0.340 0.014* 
∆IIEF EF 
Domain 0.21 ± 0.44  4.32 ± 0.71 <0.001*  
Data are means ± SEM; ∆, p1,values for baseline comparison between placebo & pioglitazone; p2, values for end point 
comparison between placebo & pioglitazone; * Significant different from placebo. 
 
 
 
Laboratory parameters 
 
At the endpoint, a significant decrease in mean 
change of total cholesterol concentration was 
observed in pioglitazone group compared to  
 
 
placebo group (-14.53 ± 4.03 vs.  3.56 ± 6.35, P = 
0.022). Compared to the baseline, LDL cholesterol 
significantly decreased in drug group (106.63 ± 
5.31 vs. 97.91 ± 5.34.  p < 0.05) but compared to 
placebo this reduction became nonsignificant. At 
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study end, TG levels in placebo group remained 
significantly higher than those in drug group but the 
mean changes in TG concentration in drug group 
vs. placebo group were nonsignificant. There were 
no correlation between the changes of total 
cholesterol levels, fasting blood glucose or other 
measured parameters and improvement of EF 
scores while an inverse correlation was found 
between the decreases of total cholesterol and age ( 
r = - 0.33 , p < 0.05).   Pioglitazone   improved 
erectile   function 
 
Table 3.  Patients % reporting improved erection (Q1) & 
sexual activity (Q2). 
 
Response to 
questions Placebo pioglitazone p value 
Positive to 
GAQ Q1 11% 58% 0.024* 
Positive to 
GAQ Q 2 11% 58% 0.024* 
  
irrespective of glucose level. Pioglitazone did not 
influence serum level of T and DHEAS in either 
group. Other laboratory parameters as well as BMI 
and W/H in drug group did not change significantly 
compared to those in control group. 
 Mild and transient adverse events were detected 
in only two patients receiving pioglitazone, ie, 
symmetrical hand edema and urinary frequency. 
Treatment with pioglitazone was generally well 
tolerated and with respect to co-administration of 
pioglitazone and sildenafil, no clinical drug 
interaction was observed. Treatment with 
pioglitazone improved urinary flow of one patient 
with slow-flowing urine. 
 
DISCUSSION 
 
Pioglitazone treatment significantly improved 
sildenafil responsiveness in men with erectile 
dysfunction who initially did not gain adequate 
response from sildenafil therapy alone. Since the 
duration of the study was not thoroughly sufficient 
for pioglitazone to exert its anti-diabetic action (20) 
and fasting blood glucose was not significantly 
influenced by the intervention, the ED improvement 
is likely irrespective of serum glucose level. This 
intervention, performed in the present preliminary 
study, appears to be safe and had no unfavorable 
effects on the measured markers.  
 To our knowledge the current study is the only 
clinical investigation that evaluated the effects of a 
PPARγ agonist in ED. Risk factors for 
cardiovascular disease could affect every integrated 
part of systemic vessels especially penile 
vasculature. Since clinically significant penile 
vascular disease precedes overt atherosclerosis in 
other arteries, e.g. coronary artery (28), ED itself 
might be potentially used as a pre-screening tool for 
evaluation of cardiovascular disease and its risk 
factors (5). As seen in many subjects participated in 
the present study, hyperlipidemia and especially 
hypercholesterolemia, were diagnosed for the first 
time, during the initial work up for ED and there 
was a co-incidence of ED with co-morbid diseases 
among sildenafil nonresponders. In drug and 
control groups, high incidence of risk factors 
including diabetes, hypertension, dyslipidemia, 
smoking along with the upper borders of the normal 
ranges in mean levels of serum glucose, cholesterol, 
LDL, TG, W/H and BMI were observed before the 
intervention. These findings are in consistence with 
those of other reports (27, 29).  
 
 
Figure 1.  Effects of placebo and pioglitazone on the EF 
domain of IIEF at baseline and at 9 weeks.                    
*p < 0.05  for endpoint comparison with placebo 
 
 Some evidence could help to figure out 
potential mechanisms for improvement of ED in 
this study. Endothelium-dependent vasodilation is 
impaired by high cholesterol (30) and cholesterol-
lowering therapy could ameliorate endothelium-
dependent relaxation (31). In the present study, 
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improvement of ED coincided with lowering of 
total serum cholesterol by pioglitazone as shown by 
other cholesterol lowering therapies such as statins 
(32). Although a significant correlation was not 
detected between these two parameters, more 
extensive studies are needed to clarify if there is a 
cause and effect relation. 
 It has been suggested that baseline EF score and 
apolipoprotein B determine responsiveness to 
sildenafil (33). Although apolipoproteins were not 
measured in this study but pioglitazone does exert 
apolipoprotein B-lowering effect (34). Thus, ED 
improvement, at least in part, could be attributed to 
this effect (34). 
 Niric-oxide (NO) production and release is 
augmented by thiazolidinediones (TZDs) at cellular 
level (35, 36). Also, pioglitazone increases NO 
bioavailability and improves endothelium 
dependent vasodilation through increasing  
adiponectin and insulin sensitivity or decreasing C- 
reactive protein (CRP), free fatty acids (FFA) and 
asymmetric dimethylarginine (ADMA) (19, 34, 37). 
Inhibition of Rho/Rho-kinase signaling 
pathway by pioglitazone (38) might be one of the 
mechanisms for ED amelioration in our patients. 
This pathway was up-regulated in the corporal 
vasculature of diabetic rats with ED and its 
inhibition might enhance suppressed penile eNOS 
expression and cGMP levels, to restore erectile 
function (39). 
 In the only animal study that investigated the 
effects of pioglitazone in veno-oclusive model of 
diabetic erectile dysfunction, pioglitazone 
decreased apoptotic index, relative collagen content 
(collagen/SMC area) and collagen III/I ratios in 
corpous cavernosa (CC) along with a reduction in 
systemic oxidative stress in 9 weeks. In long term 
piogitazone even prevented corporal veno-occlusive 
dysfunction and improved papaverin response (20). 
However, this study is incomparable with ours in 
study groups and dose equivalency. 
 In the current study, pioglitazone was preferred 
to rosiglitazone, with a conservative dose of 
30mg/day to optimize the balance between probable 
clinical responses and side effects. Apart from high 
safety data of pioglitazone (40, 41), there is a 
potential for interaction of rosiglitazone with 
sildenafil to augment the systemic effects of NO, as 
rosiglitazone has shown direct coronary 
vasodilatory effects while pioglitazone has not (42). 
Furthermore, with a local lower cost, pioglitazone 
has shown more favorable effects on lipid profile 
compared to unfavorable properties of rosigitazone 
(43, 44). Meta-analyses suggested an increased 
cardiovascular risk associated with rosiglitazone 
therapy (44). 
 To our knowledge, the current study for the first 
time showed the impact of pioglitazone on serum 
level of T and DHEAS in men. In the only one 
previous study, rosiglitazone decreased the 
production rate of T in one week (45) but the latter 
and present study are different in medication, 
sample size, duration, characteristics of subjects and 
measurement methods. There is no report of 
impotence and decreased libido following  
pioglitazone therapy (40, 41). In the current study 
after the intervention, the mean levels of total T and 
DHEAS did not change significantly. 
 Small sample size might be regarded as a 
limitation for present study but to gain stepwise 
experiences in the lack of background clinical study 
of pioglitazone in ED, our sample size seems to be 
adequately large to fulfill the main initial objectives 
of the study although this sample size is not 
sufficient to entirely address the safety of the 
intervention.  
 The mean change of EF scores was almost 
clinically significant, based on IIEF scores 
interpretation (22), and also consistently supported 
by results of GAQs. This increase in mean score 
was not much more than 4 in pioglitazone group. 
The relative short period of the intervention might 
be responsible for this result and also for the 
insignificant impact of the intervention on the most 
of serum lipids.  
 In post follow-up visits, nearly 40% of drug 
group subjects decided to continue using 
pioglitazone to maintain improved erectile function 
and attain glucose control. Many of 
vasculoprotective effects of pioglitazone appear 
gradually (20) and, thus, in long-term treatment the 
EF scores could increase more than what we 
observed. In such condition, pioglitazone may also 
influence high glucose levels, if any, and the results 
must be interpreted accordingly. On the contrary to 
many similar studies, the negligible improvement of 
ED in our placebo group shows an unaccountable 
positive psychogenic feedback in the patients thus 
the ED improvement in drug group may be devoid 
of considerable psychogenic origin and almost 
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could be attributed to the pharmacological 
properties of pioglitazone. 
 Urinary symptoms associated with pioglitazone 
treatment could be attributed to water retention in 
renal collecting ducts (34). Finally, by considering 
the present study as a preliminary evaluation of the 
benefits/risks of pioglitanzone treatment in ED 
patients, the results of this study could be 
implemented with optimization for a large trial. 
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